EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

23 April 2021
EMA/PDCO/245494/2021
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 20-23 April 2021

Chair: Koenraad Norga – Vice-Chair: Sabine Scherer

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

Due to restricted involvement, the Chair Koenraad Norga was replaced by the Vice-chair Sabine Scherer for the voting on agenda topic 3.1.45.

1.2. Adoption of agenda

PDCO agenda for 20-23 April 2021

The agenda for 20-23 April 2021 meeting was adopted.

1.3. Adoption of the minutes

PDCO minutes for 23-26 March 2021

The minutes for 23-26 March 2021 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / Deferoxamine mesylate / Alpha-ketoglutaric acid / Arginine / Alanine / Glycine / Aspartic acid / Tryptophan / N-acetyl-histidine (monohydrate) / Histidine / Calcium chloride (dihydrate) / Magnesium chloride (hexahydrate) / Potassium chloride / Sodium chloride - EMEA-002735-PIP01-19

Dr. Franz Köhler Chemie GmbH; Cardioplegia

Day 120 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application, the PDCO agreed on a PIP for the proposed medicinal product covering the entire paediatric population in the condition of cardioplegia and agreed to grant a deferral.

2.1.2. Sotatercept - EMEA-002756-PIP01-19

Acceleron Pharma; pulmonary arterial hypertension

Day 120 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application, the PDCO agreed on a PIP for sotatercept in the condition, treatment of pulmonary arterial hypertension, and to grant a waiver on its own motion in children from birth to less than 1 year of age on the grounds that the proposed medicinal product was likely to be unsafe in this population. This was justified by the new mechanism of action of the proposed medicinal product, and by the potential renal and reproductive toxicity, which were considered more relevant than the limited therapeutic benefit in this age group.

2.1.3. Human plasma derived c1-inhibitor - EMEA-002818-PIP01-20

Octapharma Pharmazeutika Produktionsges.m.b.H; Treatment of hereditary angioedema

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

The Committee adopted a positive opinion, including a deferral for Part 2 of the paediatric clinical study and a waiver in children from birth to less than 2 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2.1.4. Iscalimab - EMEA-002842-PIP01-20

Novartis Europharm Limited; Prophylaxis of solid organ transplant rejection

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

In a written response the applicant addressed the remaining issues raised by the committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for the paediatric population from 2 years of age, in the condition of prophylaxis of solid organ transplant rejection was adopted. The PDCO agreed on a waiver in a subset of children on the grounds that the specific medicinal product is likely to be unsafe in that subset. The PDCO granted a deferral for the completion of this PIP.

2.1.5. Ravulizumab - EMEA-001943-PIP03-20

Alexion Europe SAS; Treatment of myasthenia gravis

Day 120 opinion

Neurology

Summary of Committee discussion:

In conclusion, the PDCO adopted a positive opinion for ravulizumab for the treatment of myasthenia gravis with a deferral and a waiver in children from birth to less than 6 years of age on the ground of lack of significant therapeutic benefit.

2.1.6. Erdafitinib - EMEA-002042-PIP02-20

Janssen-Cilag International N.V.; Treatment of all conditions included in the category of malignant neoplasms (except urothelial carcinoma, haematopoietic and lymphoid tissue neoplasms)

Day 120 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for the age subset from 2 years to less than 18 years of age, in the condition of treatment of all conditions included in the category of malignant neoplasms (except urothelial carcinoma, haematopoietic and lymphoid tissue neoplasms) was adopted.
The PDCO agreed on a waiver in a subset of children on the grounds that the specific medicinal product is likely to be unsafe. The PDCO granted a deferral for the completion of this PIP.

2.1.7. Talazoparib - EMEA-002066-PIP01-20

Pfizer Europe MA EEIG; Treatment of Ewing sarcoma

Day 120 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for talazoparib for children age 1 to less than 18 years of age, in the condition of treatment of Ewing Sarcoma. The PDCO agreed on a waiver in children less than 1 years of age based on the ground that the disease does not occur in children.

2.1.8. Atropine sulfate - EMEA-002744-PIP01-19

Nevakar Inc.; Treatment of myopia

Day 120 opinion

Ophthalmology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children 3 years to less than 18 years of age in the condition of "treatment of myopia" was adopted. The PDCO agreed on a waiver in a subset of children less than 3 three years of age on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit. The PDCO granted a deferral for the completion of this PIP.

2.1.9. Naproxen sodium / Sumatriptan - EMEA-002959-PIP01-21

Treatment of migraine headaches

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Sumatriptan / Naproxen sodium for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of migraine headaches, based on the grounds of lack of significant therapeutic benefit.

2.1.10. Savolitinib - EMEA-002627-PIP02-21

AstraZeneca AB; Treatment of renal neoplasms

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed this procedure at Day 60 during the April 2021 plenary.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion on a product specific waiver for savolitinib for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions "treatment of renal neoplasms" on the grounds that the product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.11. Synthetic hypericin - Orphan - EMEA-002956-PIP01-21

Soligenix NL B.V; Treatment of cutaneous T-cell lymphoma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for synthetic hypericin for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of cutaneous T-cell lymphoma based on the ground of lack of significant therapeutic benefit.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need, as described above. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.12. Immunoglobulin G4 [449-cysteine], anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 gamma-4-chain), disulfide with human-Mus musculus monoclonal OG1950 kappa-chain, (232 - 232'),(235 - 235')-bis(disulfide) with immunoglobulin G4 anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 gamma-4-chain) disulfide with human-Mus musculus monoclonal OG1950 kappa-chain, 449-thioether with 1,1'-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl-1-oxopropoxy)methyl]-15-methyl-3,7,14-trioxo-9,13-dioxa-2,6-diazahexadec-1-yl]-44-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-4,8,26,42-tetraoxo-2,13,16,19,22,29,32,35,38-nonaoxa-5,9,25,41-tetraazatetratetracont-1-yl]-2-[(2-bromo-2-methyl-1-oxopropoxy)methyl]-1,3-propanediyl] bis(2-bromo-2-methylpropanoate) core 9-arm star compd. with 4-hydroxy-N,N,N,10-tetramethyl-9-oxo-3,5,8-trioxa-4-phosphaundec-10-en-1-aminium inner salt 4-oxide homopolymer (KSI-301) - EMEA-002895-PIP02-21

Kodiak Sciences Inc.; Treatment of retinal vein occlusion / Treatment of diabetic retinopathy / Treatment of choroidal neovascularisation

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver.
The PDCO granted a waiver for KSI-301 (proposed INN iridescimab vidros) for all subsets of the paediatric population (0 to 18 years of age) in the condition of Treatment of retinal vein occlusion, Treatment of diabetic retinopathy and treatment of choroidal neovascularisation.

2.1.13. Bamlanivimab - EMEA-002952-PIP01-21

Eli Lilly and Company Limited; Treatment of Covid-19

Day 90 Opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application as revised in response to the PDCO request for modification, a positive opinion for the PIP for the proposed medicine for the paediatric population from birth to less than 18 years of age, in the condition of prevention of Coronavirus disease 2019 (COVID-19) was adopted by the PDCO. The PDCO granted a deferral for the completion of this PIP.

2.1.14. Etesevimab - EMEA-002966-PIP01-21

Eli Lilly and Company Limited; Treatment Covid-19

Day 90 Opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application as revised in response to the PDCO request for modification, a positive opinion for the PIP for the proposed medicine for the paediatric population from birth to less than 18 years of age, in the condition of prevention of Coronavirus disease 2019 (COVID-19) was adopted by the PDCO. The PDCO granted a deferral for the completion of this PIP.

2.1.15. Zorecimeran - EMEA-002986-PIP01-21

CureVac AG; Prevention of Coronavirus disease 2019 (COVID-19)

Day 60 Opinion

Vaccines / Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application as revised in response to the PDCO request for modification, a positive opinion for the PIP for the proposed medicine for the paediatric population from birth to less than 18 years of age, in the condition of prevention of

Coronavirus disease 2019 (COVID-19) was adopted by the PDCO. The PDCO granted a deferral for the completion of this PIP.

2.2. Opinions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

2.2.1. Afatinib - EMEA-C-001596-PIP02-17-M02

Boehringer Ingelheim International GmbH; Treatment of malignant neoplasms of the central nervous system

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO adopted on 23 April 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision P/0184/2020 of 13 May 2020.

2.2.2. Ticagrelor - EMEA-C4-000480-PIP01-08-M13

AstraZeneca AB; Prevention of thromboembolic events

Day 30 letter

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of Committee discussion:

Compliance was checked for Study 13, a multi-centre, double-blind, randomised, placebo-controlled study to compare the effect of ticagrelor versus placebo for the reduction of vaso-occlusive crises in paediatric patients with sickle cell disease. This study is confirmed to be compliant as set out in the latest EMA Decision (P/0217/2020 of 17 June 2020).

2.2.3. Palovarotene - EMEA-C2-001662-PIP01-14-M04

Ipsen Pharma; Treatment of fibrodysplasia ossificans progressiva

Day 30 letter

Other

Summary of Committee discussion:

Compliance was checked for Study 6, a longitudinal, non-interventional two-part (A and B) study to determine the natural course of the disease for 36 months in subjects with fibrodysplasia ossificans progressiva. The study is compliant with the latest PIP as set out in the latest EMA Decision (P/0441/2020 of 1 December 2020

2.2.4. Secukinumab - EMEA-C-000380-PIP01-08-M04

Novartis Europharm Ltd; Treatment of psoriasis

Day 30 opinion

Dermatology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-000380-PIP01-08
- EMEA-C2-000380-PIP01-08-M04

The PDCO adopted on 20 April an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0352/2017) of 1 December 2017.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit), Paullinia cupana Kunth, Theobroma cacao L. - EMEA-001835-PIP01-15-M05

LEGACY HEALHCARE; Treatment of alopecia

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0321/2019 of 10 September). The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Denosumab - EMEA-000145-PIP02-12-M04

Amgen Europe B.V.; Treatment of osteoporosis

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

The PDCO noted in April 2021 the responses provided by the applicant to the issues raised at Day 30 .
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0001/2021 of 5/1/2021).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Sotagliflozin - EMEA-001517-PIP02-14-M03

Guidehouse Germany GmbH; Treatment of type 1 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0337/2017. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Linaclotide - EMEA-000927-PIP01-10-M06

Allergan Pharmaceuticals International Limited; Treatment of functional constipation

Day 60 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0135/2020 of 15 April 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Betibeglogene autotemcel - Orphan - EMEA-001665-PIP01-14-M05

bluebird bio (Netherlands) B.V.; Treatment of β-thalassaemia

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0008/2021 of 15/01/2021).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Setmelanotide - Orphan - EMEA-002209-PIP01-17-M02

Rhythm Pharmaceuticals, Inc; Treatment of appetite and general nutrition disorders

Day 60 opinion

Nutrition

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan and after reviewing the additional clarification points to issues 3 and 4 from day 30, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0179/2020 of 15/05/2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Venetoclax - Orphan - EMEA-002018-PIP02-16-M04

AbbVie Ltd; Treatment of solid tumour malignant neoplasms / Treatment of haematopoietic and lymphoid malignant neoplasms

Day 60 opinion

Oncology / Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan and the additional information provided, the PDCO considered that proposed changes to the study design and timelines could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0375/2020 of 09 September 2020).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.
The committee noted the additional information received by the applicant on the outstanding issues raised by the PDCO during the D30 discussion. Overall, all issues were considered adequately justified and addressed.

2.3.8. Highly purified single-stranded, 5'-capped mRNA encoding full-length SARS-CoV-2 spike protein (BNT162b2) - EMEA-002861-PIP01-20-M01 (discussed at the extraordinary PDCO plenary meeting held on the 9th April 2021)

BioNTech Manufacturing GmbH; SARS-CoV-2 (COVID-19) infection prevention

Day 30 discussion

Vaccines

Summary of Committee discussion:

The PDCO agreed with the proposed modifications to study 2 and study 3 of the PIP. A positive opinion was adopted by the Committee.

2.4. Opinions on Re-examinations

No item

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

No item

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. Tirzepatide - EMEA-C1-002360-PIP01-18

Eli Lilly and Company Ltd; Treatment of type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Finerenone - EMEA-001623-PIP03-20

Treatment of Heart Failure

Day 90 discussion

Cardiovascular Diseases

3.1.2. Macitentan - Orphan - EMEA-001032-PIP03-19

Janssen-Cilag International N.V.; Treatment of functional univentricular heart disease with total cavo-pulmonary connection

Day 90 discussion

Cardiovascular Diseases

3.1.3. Ralinepag - Orphan - EMEA-002432-PIP02-20

United Therapeutics Corporation; Treatment of pulmonary arterial hypertension

Day 90 discussion

Cardiovascular Diseases

3.1.4. Allogeneic skin-derived ABCB5-positive mesenchymal stem cells - Orphan - EMEA-002875-PIP01-20

RHEACELL GmbH & Co. KG; Treatment of epidermolysis bullosa

Day 90 discussion

Dermatology

3.1.5. Adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene (DTX401) - Orphan - EMEA-002734-PIP01-19

Ultragenyx Germany GmbH; Glycogen storage disease type Ia / Treatment of glycogen storage disease type Ia

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.6. Pyridoxal 5'-phosphate monohydrate - Orphan - EMEA-002404-PIP01-18

Medicure Pharma Europe Limited; Pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.7. Maralixibat Chloride - Orphan - EMEA-001475-PIP04-20

Mirum Pharmaceuticals Inc.; Treatment of biliary atresia

Day 90 discussion

Gastroenterology-Hepatology

3.1.8. Odevixibat - Orphan - EMEA-002054-PIP03-20

Albireo AB; Treatment of Alagille syndrome

Day 90 discussion

Gastroenterology-Hepatology

3.1.9. Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8 - Orphan - EMEA-002856-PIP01-20

Allakos Inc; Treatment of eosinophilic gastrointestinal inflammatory disorders

Day 90 discussion

Gastroenterology-Hepatology

3.1.10. Pralsetinib - EMEA-002575-PIP02-20

Treatment of thyroid neoplasms

Day 90 discussion

Oncology

3.1.11. Autologous selected renal cells - EMEA-002844-PIP01-20

Treatment of chronic kidney disease

Day 90 discussion

Uro-nephrology

3.1.12. EMEA-002958-PIP01-21

Treatment of hypertrophic cardiomyopathy

Day 60 discussion

Cardiovascular Diseases

3.1.13. EMEA-002962-PIP01-21

Treatment of elevated cholesterol

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.14. Drospirenone - EMEA-001495-PIP02-21

Treatment of endometriosis

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.15. Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1) - Orphan - EMEA-002955-PIP01-21

Ascendis Pharma Bone Diseases A/S; Treatment of hypoparathyroidism

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.16. Tildacerfont - Orphan - EMEA-002970-PIP01-21

Spruce Biosciences, Inc.; Treatment of congenital adrenal hyperplasia

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.17. Nangibotide - EMEA-002953-PIP01-21

Septic shock / Treatment of septic shock in children

Day 60 discussion

Infectious Diseases

3.1.18. Tosatoxumab - Orphan - EMEA-002506-PIP03-21

Aridis Pharmaceuticals Inc; Treatment of Staphylococcus aureus pneumonia

Day 60 discussion

Infectious Diseases / Pneumology - Allergology

3.1.19. Human SARS-CoV-2 immunoglobulin - EMEA-002911-PIP01-20

Treatment of coronavirus disease 2019 (COVID-19) / Treatment of hospitalised patients with COVID-19 disease

Day 60 discussion

Other

Note: Withdrawal request received on 9 April 2021

3.1.20. Human SARS-CoV-2 immunoglobulin - EMEA-002912-PIP01-20

Treatment of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Other

Note: Withdrawal request received on 7 April 2021

3.1.21. Selatogrel - EMEA-002967-PIP01-21

Treatment of acute myocardial infarction (AMI)

Day 30 discussion

Cardiovascular Diseases

3.1.22. SERALUTINIB - Orphan - EMEA-002972-PIP01-21

Gossamer Bio 002 Limited; Treatment of Pulmonary Arterial Hypertension.

Day 30 discussion

Cardiovascular Diseases

3.1.23. Vupanorsen - EMEA-002973-PIP01-21

Prevention of cardiovascular events / Treatment of hypertriglyceridaemia

Day 30 discussion

Cardiovascular Diseases

3.1.24. Ruxolitinib - EMEA-002618-PIP03-21

Atopic dermatitis

Day 30 discussion

Dermatology

3.1.25. Mannitol - EMEA-002968-PIP01-21

Bowel cleansing prior to clinical procedure

Day 30 discussion

Gastroenterology-Hepatology

3.1.26. Benzylamine derivative of benzofuran - EMEA-002974-PIP01-21

Treatment of paroxysmal nocturnal haemoglobinuria

Day 30 discussion

Haematology-Hemostaseology

3.1.27. Anti-C1s Humanized IgG4 Monoclonal Antibody - EMEA-002903-PIP02-21

Treatment of Cold Agglutinin Disease

Day 30 discussion

Immunology-Rheumatology-Transplantation / Haematology-Hemostaseology / Neurology

3.1.28. EMEA-002963-PIP01-21

Treatment of Coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.1.29. Ravulizumab - EMEA-001943-PIP04-20

Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Day 30 discussion

Neurology

3.1.30. Satralizumab - Orphan - EMEA-001625-PIP02-21

Roche Registration GmbH; Treatment of myasthenia gravis

Day 30 discussion

Neurology

3.1.31. Vatiquinone - EMEA-001238-PIP03-21

Treatment of Friedreich Ataxia

Day 30 discussion

Neurology

3.1.32. EMEA-002975-PIP01-21

Visualisation of prostate specific membrane antigen (PSMA) overexpressing tumors

Day 30 discussion

Oncology

3.1.33. Datopotamab deruxtecan - EMEA-002976-PIP01-21

Treatment of non-small cell lung cancer

Day 30 discussion

Oncology

3.1.34. Human Papilloma Virus Type 16 E6 001-032/Human Papilloma Virus Type 16 E6 019-050/Human Papilloma Virus Type 16 E6 041-065/Human Papilloma Virus Type 16 E6 055-080/Human Papilloma Virus Type 16 E6 085-109/Human Papilloma Virus Type 16 E6 091-122/Human Papilloma Virus Type 16 E6 127-158 / Human Papilloma Virus Type 16 E6 071-095/Human Papilloma Virus Type 16 E6 109-140/Human Papilloma Virus Type 16 E7 001-035/Human Papilloma Virus Type 16 E7 022-056/Human Papilloma Virus Type 16 E7 064-098 - EMEA-001055-PIP02-21

Treatment of HPV16 positive malignancies

Day 30 discussion

Oncology

3.1.35. Nirogacestat hydrobromide - Orphan - EMEA-002971-PIP01-21

SpringWorks Therapeutics, Inc; Treatment of desmoid tumours

Day 30 discussion

Oncology

3.1.36. Patritumab deruxtecan - EMEA-002977-PIP01-21

Treatment of non-small cell lung cancer

Day 30 discussion

Oncology

3.1.37. Ribociclib - EMEA-002765-PIP02-21

Treatment of neuroblastoma

Day 30 discussion

Oncology

3.1.38. Trastuzumab deruxtecan - EMEA-002978-PIP01-21

Treatment of non-small cell lung cancer

Day 30 discussion

Oncology

3.1.39. 2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA - Orphan - EMEA-002981-PIP01-21

Antisense Therapeutics Limited; Duchenne muscular dystrophy

Day 30 discussion

Other

3.1.40. Dapagliflozin propanediol monohydrate / Zibotentan - EMEA-002969-PIP01-21

Treatment of Chronic Kidney Disease

Day 30 discussion

Other

3.1.41. Pamrevlumab - Orphan - EMEA-002979-PIP01-21

FibroGen, Inc.; Duchenne Muscular Dystrophy

Day 30 discussion

Other

3.1.42. Evenamide - EMEA-002519-PIP03-21

Treatment of Schizophrenia

Day 30 discussion

Psychiatry

3.1.43. Neisseria meningitidis serogroup B Protein-based active substance / Recombinant Neisseria meningitidis serogroup B protein 1 / Recombinant Neisseria meningitidis serogroup B protein 3 / Recombinant Neisseria meningitidis serogroup B protein 2 - EMEA-002954-PIP02-21

Prevention of Meningococcal disease (serogroup B)

Day 30 discussion

Vaccines

3.1.44. Bamlanivimab - EMEA-002952-PIP01-21 (discussed at the extraordinary PDCO plenary meeting held on the 9th April 2021)

Treatment of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.45. Etesevimab - EMEA-002966-PIP01-21 (discussed at the extraordinary PDCO plenary meeting held on the 9th April 2021)

Treatment of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.46. Tixagevimab - EMEA-002900-PIP01-20 (discussed at the extraordinary PDCO plenary meeting held on the 9th April 2021)

Prevention or treatment of COVID-19

Day 60 discussion

Infectious Diseases

3.1.47. Cilgavimab - EMEA-002925-PIP01-20 (discussed at the extraordinary PDCO plenary meeting held on the 9th April 2021)

Prevention or treatment of COVID-19

Day 60 discussion

Infectious Diseases

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Velmanase alfa - EMEA-C-001056-PIP02-12-M01

Chiesi Farmaceutici S.p.A; Treatment of alpha-mannosidosis

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.2.2. Mitapivat - EMEA-C1-002684-PIP01-19

Agios Netherlands B.V.; Treatment of pyruvate kinase deficiency

Day 30 discussion

Haematology-Hemostaseology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Nemolizumab - EMEA-001624-PIP01-14-M03

Galderma International S.A.; Atopic dermatitis

Day 30 discussion

Dermatology

3.3.2. Bis-choline tetrathiomolybdate - Orphan - EMEA-002232-PIP02-19-M01

Alexion Europe S.A.S.; Treatment of Wilson Disease

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.3. Canagliflozin (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate - EMEA-001030-PIP01-10-M09

Janssen-Cilag International NV; Type 2 Diabetes Mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.4. Cotadutide - EMEA-002287-PIP01-17-M02

AstraZeneca AB; Treatment of Type 2 Diabetes Mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.5. Romosozumab - EMEA-001075-PIP04-15-M03

UCB Pharma S.A.; Treatment of osteoporosis

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. Eluxadoline - EMEA-001579-PIP01-13-M04

Allergan Pharmaceuticals International Limited; Treatment of diarrhoea-predominant irritable bowel syndrome

Day 30 discussion

Gastroenterology-Hepatology

3.3.7. Ozanimod hydrochloride - EMEA-001710-PIP03-17-M03

Celgene Europe B.V.; Treatment of ulcerative colitis

Day 30 discussion

Gastroenterology-Hepatology

3.3.8. Garadacimab - EMEA-002726-PIP01-19-M01

CSL Behring GmbH; Prevention of hereditary angioedema attacks

Day 30 discussion

Haematology-Hemostaseology

3.3.9. Cotadutide - EMEA-002712-PIP01-19-M01

AstraZeneca AB; Treatment of non-alcoholic steatohepatitis (NASH)

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.10. Guselkumab - EMEA-001523-PIP03-18-M01

Janssen-Cilag International NV; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.11. Rilzabrutinib - Orphan - EMEA-002438-PIP02-19-M01

Principia Biopharma, Inc.; Treatment of immune thrombocytopenia

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.12. Cobicistat / darunavir - EMEA-001280-PIP01-12-M04

Janssen-Cilag International NV; Treatment of HIV-1 Infection

Day 30 discussion

Infectious Diseases

3.3.13. Dolutegravir (DTG) - EMEA-000409-PIP01-08-M06

ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.14. Ibalizumab - EMEA-002311-PIP01-17-M02

Theratechnologies Europe Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.15. Oseltamivir phosphate - EMEA-000365-PIP01-08-M12

Roche Registration GmbH; Treatment and prevention of influenza

Day 30 discussion

Infectious Diseases

3.3.16. Oteseconazole - EMEA-002392-PIP01-18-M01

Gedeon Richter Plc.; Treatment of vulvovaginal candidiasis

Day 30 discussion

Infectious Diseases

3.3.17. Peramivir - EMEA-001856-PIP02-16-M02

BioCryst Ireland Limited; Treatment of influenza

Day 30 discussion

Infectious Diseases

3.3.18. Tenofovir alafenamide - EMEA-001584-PIP01-13-M06

Gilead Sciences International Ltd.; Treatment of chronic viral hepatitis B

Day 30 discussion

Infectious Diseases

3.3.19. Vaborbactam / meropenem - EMEA-001731-PIP01-14-M03

Menarini International Operations Luxembourg S.A.; Treatment of Gram-negative bacterial infections

Day 30 discussion

Infectious Diseases

3.3.20. Galcanezumab - EMEA-001860-PIP03-16-M05

Eli Lilly and Company Limited; Prevention of migraine headaches

Day 30 discussion

Neurology

Note: Withdrawal request received on 2 April 2021

3.3.21. Nivolumab - EMEA-001407-PIP02-15-M05

Bristol-Myers Squibb Pharma EEIG; Treatment of malignant neoplasms of the central nervous system / Treatment of malignant neoplasms of lymphoid tissue

Day 30 discussion

Oncology

3.3.22. Lanadelumab - Orphan - EMEA-001864-PIP01-15-M05

Shire Pharmaceuticals Ireland Limited; Treatment of hereditary angioedema

Day 30 discussion

Other

3.3.23. Ravulizumab (ALXN1210) - Orphan - EMEA-001943-PIP01-16-M06

Alexion Europe SAS; Treatment of atypical Haemolytic Uremic Syndrome

Day 30 discussion

Uro-nephrology / Haematology-Hemostaseology

3.3.24. Ravulizumab (ALXN1210) - Orphan - EMEA-002077-PIP01-16-M04

Alexion Europe SAS; Paroxysmal Nocturnal Haemoglobinuria

Day 30 discussion

Uro-nephrology / Haematology-Hemostaseology

3.3.25. COVID-19 Vaccine (ChAdOx1-S recombinant) - EMEA-002862-PIP01-20-M01 (discussed at the extraordinary PDCO plenary meeting held on the 9th April 2021)

AstraZeneca AB; COVID-19 vaccine is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2

Day 30 discussion

Vaccines

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 27 April 2021 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

5.2. Final Scientific Advice (Reports and Scientific Advice letters)

No item

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

No item

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

No item

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

No item

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Update on PDCO member(s)/alternate(s) mandate status

No item

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

No item

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The chair of the Non-clinical Working Group (NcWG) identified the products which will require NcWG evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

No item

9.5. Cooperation with International Regulators

No item

9.5.1. Report from the Paediatric Cluster Teleconference

No item

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO work plan

No item

9.8. Planning and reporting

No item

10. Any other business

10.1. COVID -19 update

Summary of Committee discussion:

The PDCO was updated on treatments and vaccines for COVID-19.

11. Breakout sessions

11.1. Paediatric oncology

Summary of Committee discussion:

This oncology breakout session was cancelled.

11.2. Neonatology

Summary of Committee discussion:

Scientific update on COVID-19 in neonates.

11.3. Internal PDCO Operations

Summary of Committee discussion:

The committee discussed PDCO internal operations.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 20-23 April 2021 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Koenraad Norga	Chair	Belgium	No participation in discussion, final deliberations and voting on:	3.1.45. Fully human neutralizing immunoglobulin G-1 kappa monoclonal antibody directed against a conserved epitope on the SARS CoV1 and 2 spike protein - EMEA-002899-PIP01-20
Karl-Heinz Huemer	Member	Austria	No interests declared	
Marleen Renard	Member	Belgium	No participation in discussion, final deliberations and voting on:	3.1.26. Ruxolitinib phosphate - EMEA-002618-PIP03-21
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Arnes Resic	Alternate	Croatia	No interests declared	
Georgios Savva	Member	Cyprus	No interests declared	
Lucie Kravackova	Member	Czechia	No interests declared	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member (Vice-Chair)	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Dovile Zacharkiene	Member	Lithuania	No interests declared	
Silvijus Abramaviciu s	Alternate	Lithuania	No restrictions applicable to this meeting	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Roderick Houwen	Member	Netherlands	No participation in final deliberations and voting on: No participation in discussion, final deliberations and voting on:	3.3.2. Bis-choline tetrathiomolybdate - Orphan - EMEA-002232-PIP02-19-M01 3.1.8. Odevixibat - Orphan - EMEA-002054-PIP03-20
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable to this meeting	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Eva Agurell	Member	Sweden	No interests declared	
Sara	Alternate	Sweden	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Vennberg				
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Catherine Cornu	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jaroslav Sterba	Member	Patients' Organisation Representative	No interests declared	
Tomasz Grybek	Alternate	Patients' Organisation Representative	No interests declared	
Michal Odermarsky	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	
María Estela Moreno Martín	Expert - via telephone*	Spain	No interests declared	
Lutz Wiesner	Expert - via telephone*	Germany	No interests declared	
Friederike Feldmann	Observer - via telephone*	Germany - BfArM	No interests declared	
Kristin Karlsson	Expert - via telephone*	Sweden	No restrictions applicable to this meeting	
Elmer Schabel	Expert - via telephone*	Germany - BfArM	No interests declared	
André Elferink	Expert - via telephone*	Netherlands	No interests declared	
Meeting run with support from relevant EMA staff				
* Experts were only evaluated against the agenda topics or activities they participated in				

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/